An optimal design for screening trials.
Yao, Begg, and Livingston (1996, Biometrics 52, 992-1001) considered the optimal group size for testing a series of potentially therapeutic agents to identify a promising one as soon as possible for given error rates. The number of patients to be tested with each agent was fixed as the group size. We consider a sequential design that allows early acceptance and rejection, and we provide an optimal strategy to minimize the sample sizes (patients) required using Markov decision processes. The minimization is under the constraints of the two types (false positive and false negative) of error probabilities, with the Lagrangian multipliers corresponding to the cost parameters for the two types of errors. Numerical studies indicate that there can be a substantial reduction in the number of patients required.
Wang
Y G
YG
CSIRO Mathematical and Information Sciences, Cleveland, Queensland, Australia. You-Gan.Wang@marine.csiro.au
Leung
D H
DH
D001699:Biometry; D002986:Clinical Trials as Topic / Q000379:methods* / Q000706:statistics & numerical data; D004341:Drug Evaluation / Q000706:statistics & numerical data; D006801:Humans; D008390:Markov Chains